


# Washington State Life Science Investment Report April 2022

A monthly report summarizing life science transactions in Washington State.


BY THE NUMBERS: **24** TRANSACTIONS TOTALING OVER **\$418M**  
(YTD)



Deals Per Sector



Disclosed Funding By Sector



## APRIL TOP TRANSACTIONS

**Aurion Biotech**, a spinoff of Seattle eye care company, CorneaGen, has received \$120M in funding to help advance cell therapy for corneal endothelial dystrophies, an eye disorder affecting millions ([GeekWire](#)).

**Receptor Life Sciences**, a Seattle-based startup, announced it has raised \$9.7M in a Series A-1 funding round to push its CBD-based therapeutic for acute anxiety into clinical testing ([GeekWire](#)).

**Salish Bioscience**, developer of liquid biopsy technology solutions that helps oncologists for the treatment of cancer, closed a \$6M seed round. Their technology circulates cell-free DNA as a biomarker and utilizes molecular biology to address the cancer (S&P Global Market Intelligence, 5/26/2022).

## OTHER TRENDS & HIGHLIGHTS

**Seagen**, the Bothell-based biotech, is building a 270,000-square-foot biomanufacturing facility in Everett. The new facility is expected to open in 2024 and employ up to 200 workers. Seagen called the facility a “greenfield” project, meaning the facility is being built from the start to be a medical production facility ([Puget Sound Business Journal](#)).

**Sana Biotechnology** is on track to remove barriers for cell and gene therapy. One of the most important transformations of 21st-century medicine will be the ability to reengineer cells as medicines and Sana Biotechnology is on the path to do that, with notable strides that may, just possibly, change medicine as we know it ([BioSpace](#)).

**AI2 Incubator**, a branch of the 200-person Allen Institute, leverages technical expertise and industry connections to help entrepreneurs build “AI first” companies. AI2 Incubators goal is to cement Paul Allen’s legacy for a new era of technology and reinforce the Seattle region’s status as an AI hub ([GeekWire](#)).

# TRANSACTIONS

Date	Company	Sector	Type	Amount	Location
7-Apr-22	Receptor Life Sciences, Inc.	Biotech	Series A	\$9,700,000	Seattle
12-Apr-22	Aurion Biotech, Inc.	Biotech	Venture	\$120,000,000	Seattle
14-Apr-22	Salish Bioscience Inc.	Biotech	Seed	\$6,000,000	Seattle
19-Apr-22	Optimize Systems Inc.	Digital Health	Private Placement	\$2,000,000	Seattle
25-Apr-22	Histion	Biotech	Merger/ Acquisition	Undisclosed	Everett
30-Apr-22	Asha AI	Digital Health	Pre-Seed	\$225,000	Seattle
<b>April Total (disclosed transactions): \$137,925,000</b>					
<b><u>March Total (disclosed transactions): \$18,590,000</u></b>					
<b><u>February Total (disclosed transactions): \$159,410,000</u></b>					
<b><u>January Total (disclosed transactions): \$102,390,000</u></b>					